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Abstract
Background: This study was designed to evaluate the efficacy and safety of fulranumab, a fully human monoclonal
antibody directed against nerve growth factor (NGF), for pain relief in patients with interstitial cystitis/bladder pain
syndrome (IC/BPS).
Methods: In this multicenter, double-blind study, adults with IC/BPS (i.e., interstitial cystitis symptom index [ICSI]
total score ≥8) accompanied by chronic, moderate-to-severe pain were randomized to fulranumab 9 mg or
matching placebo, administered subcutaneously at weeks 1, 5, and 9. The primary efficacy endpoint was change
from baseline to study endpoint (week 12 or at withdrawal) in average daily pain intensity score. Key secondary
endpoints included change from baseline to study endpoint in worst pain intensity score, ICSI total score, Pelvic
Pain and Urgency/Frequency total score, Patient Perception of Bladder Condition score, and global response
assessment.
Results: This study was terminated prematurely based on concern that this class may be associated with rapidly
progressing osteoarthritis or osteonecrosis. Thirty-one patients (of the targeted 70 patients) were randomized, 17 to
placebo and 14 to fulranumab, with 15 and 10 patients, respectively, receiving all 3 doses of double-blind
treatment. In ANOVA analyses, there was no statistically significant difference between treatment groups for the
primary endpoint (LS mean difference [95% CI] vs. placebo, −0.2 [−1.52, 1.10]) or any of the secondary endpoints.
Fulranumab was well tolerated, with no patient discontinuing due to an adverse event or experiencing a joint-
related serious adverse event over a 26-week follow-up period. No events related to the neurologic or motor
systems were reported.
Conclusions: Efficacy was not demonstrated in the present study with the single dose tested and a limited sample
size, leading to lack of statistical power. These findings do not exclude the possibility that fulranumab would
provide clinical benefit in a larger study and/or specific populations (phenotypes) in this difficult to treat pain
condition.
Trial registration: NCT01060254, registered January 29, 2010.
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Background
Pain (suprapubic related to bladder filling, pelvic, and/or
in extragenital locations such as the lower abdomen/back)
is the hallmark symptom of interstitial cystitis/bladder
pain syndrome (IC/BPS) [1]. Several lines of evidence sug-
gest that IC/BPS can be conceptualized as a bladder pain
syndrome associated with not only chronic pain, but also
voiding-related symptoms and, in many, other chronic
systemic pain disorders. As such, pain management is
central to multimodal therapeutic strategies for IC/BPS,
given its bearing on psychosocial functioning and quality
of life [2, 3]. In fact, recently published IC/BPS guidelines
from the American Urological Association recommend
pain management as first-line treatment, which should be
offered to all patients [1]. Despite the need of IC/BPS pa-
tients for analgesia, effective pharmacological treatment
for their chronic pain remains elusive [4–6].
In the midst of a growing need for alternative analge-
sics, nerve growth factor (NGF) antagonism is a focus of
drug research and development, with anti-NGF agents
in the spotlight [7]. Experimental and clinical evidence
has established the major role of NGF in the generation
and maintenance of pain states, and specifically in blad-
der pain in animal models [7–9]. Several humanized and
fully human anti-NGF monoclonal antibodies have en-
tered clinical trials as potential analgesics, with prelimin-
ary results showing significant improvement in chronic
pain from osteoarthritis [10] and diabetic peripheral
neuropathy [11, 12] and mixed results for relief of
chronic low back pain [13]. Efficacy for interstitial cyst-
itis was also tested initially with positive results [14], but
failed to show treatment effect versus placebo in a sec-
ond study of chronic prostatitis/chronic pelvic pain syn-
drome [15].
Fulranumab, a fully human recombinant monoclonal
antibody (immunoglobulin G), is a potent inhibitor of hu-
man NGF. Results from phase 2, randomized, placebo-
controlled studies of fulranumab demonstrate a positive
dose response in diabetic peripheral neuropathic pain
[11], mixed efficacy results versus placebo and statistically
significant improvement versus an opioid in pain of osteo-
arthritis [16, 17], and did not separate from placebo for
low-back pain [18]. We herein report the results of a
phase 2a study conducted to explore the efficacy and
safety profile of fulranumab, as compared to placebo, in
patients with moderate-to-severe chronic bladder pain
from IC/BPS. On December 23, 2010, the United States
Food and Drug Administration (FDA) placed ongoing ful-
ranumab studies on clinical hold because of a concern
that the entire class of anti-NGF antibodies may be associ-
ated with a condition representing either rapidly progres-
sing osteoarthritis or osteonecrosis [19]. As a result, the
sponsor discontinued this study prematurely, after having
enrolled only 31 of the targeted 70 patients.
Methods
Ethical practices
An Independent Review Board (US) or Research Ethics
Board (Canada) at each study site approved the study
protocol and protocol amendments. The study was con-
ducted in accordance with the ethical principles that have
their origin in the Declaration of Helsinki, consistent with
Good Clinical Practices and applicable regulatory require-
ments. All patients provided written informed consent be-
fore study participation. The study is registered at
clinicaltrials.gov, NCT 01060254.
Patients
Study participants were adult (≥18 to 80 years, inclusive)
men and women with IC/BPS based on a total score ≥ 8
on the validated O’Leary-Sant interstitial cystitis symp-
tom index (ICSI) [20, 21] and chronic bladder pain for
at least 6 months prior to screening, accompanied by
urinary urgency, urinary frequency (≥8 voids daily), and/
or nocturia. On the basis of patients’ self-assessment of
pain using a 11-point numerical rating scale (NRS) (0
= “no pain”, 10 = “worst pain imaginable”), the mean of
the average pain intensity scores for the last 7 days of
screening had to be ≥5 based on at least 6 of 7 days for
eligible patients [22]. Other key eligibility criteria re-
quired that patients had no evidence of a urinary tract
infection or significant urological disease, including
neurogenic bladder and diabetic cystopathy, and had not
received intravesical therapy or undergone cystoscopy
during the 6 weeks prior to screening. In addition, they
had not received opioid analgesic in a dosage of oral
morphine equivalent ≥ 40 mg/day or changed drugs
known to affect IC/BPS-associated pain (i.e., antidepres-
sants, antihistamines, antispasmodics, anticholinergics,
anticonvulsants) within the 4 weeks before screening.
Study design
This randomized, double-blind, placebo-controlled, mul-
ticenter study was conducted between March 2010 and
June 2011 (last study visit) at 12 study sites (10 in US
and 2 in Canada). Reports of spontaneous reporting of
joint replacements were collected through November
2011 (explanation provided under Safety Assessments).
The study comprised a screening period of up to
4 weeks, a 12-week double-blind treatment period, and a
post-treatment period that concluded 26 weeks after the
final dose of study drug was administered.
Eligible patients were randomized in a 1:1 ratio, based
on a computer-generated randomization schedule, to
fulranumab 9 mg or matching placebo injected subcuta-
neously (SC) into the thigh (or abdominal wall, only if
the thigh was not feasible) once every 4 weeks (i.e., at
weeks 1, 5, and 9 visits). Randomization was balanced
using randomly permuted blocks and was stratified by
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the presence versus absence of glomerulations and/or
Hunner’s ulcer on cystoscopy [23] and by baseline body
weight (<85 kg vs. ≥ 85 kg). Patients were followed dur-
ing the double-blind treatment period at clinic visits
conducted at baseline and every other week through
week 13.
If patients used regularly scheduled bladder pain medi-
cations within 3 months before screening, they could con-
tinue taking them (with no dose changes) concomitantly
with study drug. In addition, rescue use of acetaminophen
(up to 3000 mg/day) was allowed throughout the study.
Efficacy assessments
At each study visit, patients received a diary into which
they recorded a bladder pain NRS score for average and
worst pain over the previous 24 h, urinary frequency
(daytime and nocturnal), and interference with sleep for
the 7 days before clinic visits. At all clinic visits, patients
rated the degree to which their IC/BPS caused them
problems using the Patient Perception of Bladder Condi-
tion (PPBC) instrument [24] and the number of noctur-
nal awakenings for voiding, pain with sexual activity,
bladder/pelvic pain, and the frequency of bother with
these symptoms using the Pelvic Pain and Urgency/Fre-
quency Questionnaire (PUF) [25]. At selected clinic
visits (weeks 5, 9, and 13), patients also rated the pres-
ence and extent of their IC/BPS symptoms (urinary ur-
gency, urinary frequency, nocturia, pain/burning in the
bladder) by completing an ICSI questionnaire and their
overall status since beginning study medication by com-
pleting the 7-point global response assessment (GRA):
very much worse; much worse; minimally worse; not
changed; minimally improved; much improved; and very
much improved.
Safety assessments
Investigators monitored adverse events throughout the
study. They also performed other standard safety assess-
ments (i.e., clinical laboratory tests, vital signs, physical
examination) at prespecified time points.
An independent data monitoring committee, including
3 medical experts in pain and neurology and 1 statisti-
cian, reviewed unblinded safety data on an ongoing basis
to ensure patient safety. This review did not identify any
safety signal that met prespecified stopping rules.
In response to an FDA request, additional information
to assess patient’s joints was collected to evaluate
whether rapidly progressing osteoarthritis or osteonecro-
sis occurred during the study. The tests included im-
aging data and/or historical data (e.g., X-rays, MRIs,
ultrasounds, historical data pertaining to the joint re-
placement) of any joint that had been replaced or in
which a relevant joint-related adverse event occurred.
The study remained open until November 2011 to ac-
commodate this request.
Data analysis
Efficacy analyses were performed on the intent-to-treat
(ITT) data set, namely, all patients who were random-
ized, received at least 1 dose of study drug, and had at
least 1 efficacy evaluation during the double-blind treat-
ment period.
Efficacy endpoints and analyses
The primary efficacy endpoint, defined as change in
average pain intensity from the baseline bladder pain in-
tensity score at study endpoint (i.e., end of the double-
blind treatment phase or at the withdrawal visit), was
analyzed using an analysis of variance (ANOVA) model,
which included treatment group as factor. For patients
who terminated before completing 12 weeks of treat-
ment, the last observed data were carried forward to
endpoint for analysis. Analyses of secondary efficacy
endpoints were conducted using a similar ANOVA
model.
Sample size determination
In the absence of data on bladder pain effect size in IC/
BPS patients and specific effects of fulranumab, sample
size assumptions for this study were based on those
from another study [16] that was ongoing at the time
the protocol for this study was written. Assuming a
treatment difference of 1.4 in the change from baseline
in average pain intensity score between fulranumab and
placebo, a standard deviation (SD) of 2.4, and an overall
discontinuation rate of 20%, then a sample size of 35 pa-
tients per treatment group or total 70 patients in the en-
tire study would have provided 78.8% power using a
type 1 error rate of 0.1 and a 1-sided 2 sample t-test.
Results
Patients
A total of 83 patients were screened and 31 eligible pa-
tients were randomized, 17 to placebo and 14 to fulranu-
mab. On December 23, 2010, the FDA placed ongoing
fulranumab studies on clinical hold because of a concern
that the entire class of anti-NGF antibodies may be asso-
ciated with a condition representing either rapidly pro-
gressing osteoarthritis or osteonecrosis [19]. As a result,
the sponsor discontinued this study prematurely, after
having enrolled only 31 of the targeted 70 patients.
Of the 31 randomized patients, 24 completed the
study and 7 were withdrawn from the study prematurely
(Table 1). Two of 17 patients in the placebo group and 4
of 14 patients in the fulranumab group did not receive
all 3 doses of double-blind study drug.
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The treatment groups were well-matched based on
demographic and most other baseline characteristics
(Table 2). The ITT data set was composed primarily of
women (83.9%); the mean (SD) age was 48.2 (12.34) years.
Patients in the placebo group reported longer IC/BPS dis-
ease duration (mean, 9.4 vs. 5.8 years for the fulranumab
group) and higher daytime urinary frequency (mean, 16.5
vs. 10.8); mean baseline daily NRS scores for average (6.6
vs. 5.7) and worst (7.6 vs. 6.6) bladder pain scores were
similar between the treatment groups, as was the fre-
quency of nocturnal urinary frequency (4.9 vs. 3.7). Of the
UPOINT domains, the fulranumab group had a higher
percentage of patients in the infection and neurological/
systemic domains than the placebo group (Table 2).
Sixteen patients in the placebo group and 12 of 14
(86%) in the fulranumab group received concomitant
IC/BPS medications with study drug, the most common
being pentosan polysulfate sodium (PPS) (7 patients in
each treatment group); a benzodiazepine (6 and 5 pa-
tients in the placebo and fulranumab groups, respect-
ively), a corticosteroid (4 and 2 patients in the respective
groups), an antidepressant (7 and 3 patients in the re-
spective groups), an antihistamine (5 and 6 patients in
the respective groups), an anticholinergic (2 and 3 pa-
tients in the respective groups), an antispasmodic (1 and
3 patients in the respective groups), and an anti-infective
agent (3 and 2 patients in the respective groups).
Efficacy results
There was no statistically significant difference between
fulranumab and placebo for the primary efficacy end-
point (Table 3). The responder rates based on 30 and
50% improvement at the study endpoint in the average
pain intensity score were also similar between the treat-
ment groups (Fig. 1). The responder rate based on 30%
improvement in average pain score at study endpoint in
the ITT data set was 30.8% for patients treated with ful-
ranumab and 33.3% for placebo patients.
There were no statistically significant between-group
differences for any of the secondary endpoints (Table 3),
however, there was a trend of better GRA. Five (35.7%)
patients in the fulranumab group and 4 (23.5%) patients
in the placebo group reported a GRA score of “very
much improved” or “much improved”, 5 patients in each
group (35.7% and 29.4%, respectively) reported a GRA
score of “minimally improved”, and 4 (28.5%) and 8
(47.1%) patients in the respective groups reported “not
changed”, “minimally changed”, or “much worse”.
Safety results
The safety profile of fulranumab was similar to that of pla-
cebo. The most frequently reported adverse events in the
fulranumab group were diarrhea, carpal tunnel syndrome,
and urinary tract infection (Table 4). In both treatment
groups, most adverse events were mild or moderate in in-
tensity and were reported to be either not related or doubt-
fully related to the study drug. The only serious adverse
event (kidney infection) was reported in the placebo group.
Table 1 Patient disposition
Number (%) of patients
Placebo Fulranumab 9 mg
Randomized 17 (100) 14 (100)
Received all 3 doses of study drug 15 (88) 10 (71)
Completed the study 14 (82) 10 (71)
Withdrew from the study 3 (18) 4 (29)
Sponsor discontinued the study 1 (6) 0 (0)
Patient withdrew consent 2 (12) 0 (0)
Other 0 (0) 4a (29)
aTwo patients did not meet inclusion/exclusion criteria, 1 patient missed the
Week 9 dose, and 1 patient withdrew due to the clinical hold






Female 13 (76.5) 13 (92.2)
Male 4 (23.5) 1 (7.1)
Race, n (%)
White 16 (94.1) 13 (92.9)
Black or African American 1 (5.9) 1 (7.1)
Age (years)
Mean ± SD 46.2 (13.56) 50.6 (10.68)
Range 25–69 38–78
Body weight (kg)
Mean ± SD 78.9 (16.61) 71.7 (26.12)
Range 54–117 46–148
UPOINT clinical phenotyping, n (%)
Urinary 17 (100) 14 (100)
Psychosocial 5 (29) 3 (21)
Organ-specific 16 (94) 11 (79)
Infection 4 (24) 5 (36)
Neurological/systemic 7 (41) 9 (64)
Tender point 12 (71) 9 (64)
Duration of interstitial cystitis (years)
Mean ± SD 9.4 (9.87) 5.8 (5.44)
Range 2–40 1–20
Hunner’s ulcer and/or glomerulation, n
(%)
Yes 9 (52.9) 10 (71.4)
No 8 (47.1) 4 (28.6)
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No study patient discontinued study drug due to an adverse
event.
Regarding adverse events of clinical interest (related to
anti-NGF antibodies), none of the study patients had
joint-related serious adverse events. No event related to
bradycardia, hepatic failure, acute renal failure, or neuro-
logic and motor system was reported. One patient (in
the placebo group) experienced a hypotension-related
adverse event.
Discussion
In this multicenter, double-blind, randomized study of
31 adults with a diagnosis of IC/BPS who suffered from
chronic, moderate-to-severe bladder pain, a treatment





Primary Endpoint – Average Pain Intensity Scorea
Baseline, mean ± SD 6.8 ± 1.30 6.1 ± 1.11
Change at end of double-blind treatment period, mean ± SD −1.2 ± 1.88 −1.4 ± 1.41
Difference of means (95% CI) −0.2 ± 0.64 (−1.52, 1.10)
% Responders defined as:
≥ 30% improvement in average pain intensity scorea 5 (33.3%) 4 (30.8%)
≥ 50% improvement in average pain intensity scorea 3 (20.0%) 3 (23.1%)
Secondary Endpoint – Worst Pain Intensity Scorea
Baseline, mean ± SD 7.6 ± 1.32 6.9 ± 1.13
Change at end of double-blind treatment period, mean ± SD −1.5 ± 1.90 −1.5 ± 1.55
Difference of means (95% CI) −0.1 ± 0.66 (−1.44, 1.28)
Other Secondary Endpoints:
ICSI Total Scoreb
Baseline, mean ± SD 16.5 ± 2.92 14.6 ± 3.27
Change at end of double-blind treatment period, mean ± SD −3.0 ± 3.97 −4.4 ± 4.40
Difference of means (95% CI) −1.4 ± 1.50 (−4.50, 1.65)
PUF Total Scorec
Baseline, mean ± SD 26.2 ± 6.86 24.3 ± 4.89
Change at end of double-blind treatment period, mean ± SD −4.2 ± 5.38 −6.1 ± 5.16
Difference of means (95% CI) −1.9 ± 1.91 (−5.81, 1.99)
PPBC Scored
Baseline, mean ± SD 4.9 ± 0.86 4.7 ± 0.61
Change at end of double-blind treatment period, mean ± SD −0.5 ± 1.12 −0.9 ± 1.23
Difference of means (95% CI) −0.3 ± 0.42 (−1.19, 0.54)
Daytime urinary frequencye
Baseline, mean ± SD 16.5 ± 11.66 11.0 ± 6.68
Change at end of double-blind treatment period, mean ± SD 0.8 ± 3.92 0.5 ± 2.95
Difference of means (95% CI) −0.3 ± 1.33 (−3.02, 2.44)
Nocturnal urinary frequencye
Baseline, mean ± SD 5.0 ± 4.36 3.8 ± 3.28
Change at end of double-blind treatment period, mean ± SD 0.6 ± 5.33 −0.4 ± 1.33
Difference of means (95% CI) −1.0 ± 1.52 (−4.16, 2.09)
ICSI O’Leary-Sant Interstitial Cystitis Symptoms Index, PPBC Patient Perception of Bladder Condition, PUF Pelvic Pain and Urgency/Frequency Questionnaire
aAn 11-point scale, ranging from 0 (“no pain”) to 10 (“pain as bad as you can imagine”)
bSum of 4 individual question ratings, each on a 0 to 5 scale, where higher scores indicate worse symptoms
cA 12-item scale, with total score (sum of the symptom and bother subscale scores) ranging for 0 to 35; higher scores indicate worse symptoms
dSingle item global measure of bladder condition rated on a 6-point scale
eDerived as an average number of events over the 7 consecutive days prior to each visit
Mean of all non-missing scores after first dose and up to last non-missing score for the 12-week double-blind period
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effect (vs. placebo) was not observed with fulranumab,
based on the primary study endpoint or any of the
secondary endpoints. A trend for improvement was ob-
served on the GRA, considering all subcategories, how-
ever this finding needs to be confirmed. Patient
enrollment was curtailed at an early stage due to a regu-
latory hold on clinical studies, preventing complete effi-
cacy and safety analysis, reducing power (from 79 to
52%), and limiting conclusions. In addition, an imbal-
ance in the baseline characteristics of the two treatment
groups was detected, further diminishing the ability to
definitively rule out a potential treatment effect. The de-
velopment of anti-NGF antibodies was re-initiated in
2015 in patients with osteoarthritis and low back pain
(NCT02301234, NCT0252818, NCT02528253, and
NCT02683239; at clinical trials.gov). Further develop-
ment of anti-NGF agents in patients with IC/BPS will be
dependent on the safety profile observed in the osteo-
arthritis and low back pain studies.
The therapy of IC/PBS is usually multimodal and is
rarely satisfactory [26–28]. With the exception of PPS
(Elmiron), there are currently no approved pharmacologic
therapies in the United States for IC/BPS. Many pharma-
cologic therapies such as antidepressants and antihista-
mines are used off label. Other therapies include
intravesical installation of agents, bladder distention, and
surgical intervention [26–28]. Promising agents have been
studied, but with mixed results, and none have gained
regulatory approval. In this regard, Evans et al. reported
significant improvement in pain and the GRA 6 weeks
after a single IV infusion of another anti-NGF monoclonal
antibody, but no improvement on the ICSI in a pilot study
of 64 patients with IC/BPS [14]. The same anti-NGF anti-
body was tested in a second clinical study of over 200 pa-
tients with IC/BPS that was terminated for futility
(NCT00999518) [29].
Limitations of this study were early termination of the
study resulting in small sample size and some patients
not receiving 3 doses of study drug, as well as imbalance
between the treatment groups based on baseline charac-
teristics. For example, patients in the placebo group re-
ported longer IC/BPS disease duration (mean, 9.4 vs.
5.8 years for the fulranumab group) and higher daytime
urinary frequency (mean, 16.5 vs. 10.8); and of the
UPOINT domains, the fulranumab group had a higher
percentage of patients in the infection and neurological/
systemic domains than the placebo group (Table 2). In
addition, due to the heterogeneous population, multiple
factors that are impractical to stratify may confound or
increase the noise of the study; these include concomi-
tant IC/BPS medication types/rate of usage, and
Fig. 1 Distribution of Pain Responder Rates at the Study Endpoint
Table 4 Treatment-emergent adverse events reported in ≥10%





Any adverse event 11 (65%) 8 (57%)
Diarrhea 2 (12) 3 (21)
Carpal tunnel syndrome 0 2 (14)
Urinary tract infection 2 (12) 2 (14)
Pain 2 (12) 0
Pain in extremity 2 (12) 0
Paresthesia 2 (12) 0
Sinusitis 2 (12) 0
Adverse events are presented in decreasing order of incidence for the
fulranumab group
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commonly comorbid conditions (e.g., irritable bowel dis-
ease, depression, pelvic floor dysfunctional disease) that
define different clinical phenotypes [30].
Clinical trials of IC/BPS have been limited, in general,
by substantial heterogeneity in methodology, symptoms
assessment, duration of treatment, and follow-up [31].
For example, although initial trials were positive for PPS
[32, 33], subsequent large confirmatory trials have had
mixed results [34]. Experts have recently advanced the
use of clinical phenotypes based on UPOINT or pain
mapping/pain location in IC/BPS research [30, 35]. With
regard to analgesia for IC/BPS, future studies should in-
clude mapping of pain sites (i.e., restricted to the pelvis;
pain sites beyond the pelvis) and the quality/severity of
pain at those sites, assuring differentiation between IC/
BPS and other pain syndromes by patients, as well as
correlate findings from these assessments with associ-
ated comorbid, chronic pain conditions [30]. While this
study was designed to collect data pertaining to the dif-
ferent clinical phenotypes using the UPOINT system
and conduct exploratory subgroup analyses, these ana-
lyses were not feasible due to early study termination
and the reduced sample size. Future studies of adequate
sample size should further explore treatment response
according to clinical phenotypes.
Conclusions
In patients with moderate to severe chronic bladder pain
from IC/BPS, fulranumab at the single dose (9 mg)
tested failed to show analgesic activity as compared with
placebo, although the study findings are limited by early
study termination and imbalance in the baseline charac-
teristics of the study population. IC/BPS remains a diffi-
cult medical condition in need of satisfactory therapies.
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